Endocrine Abstracts

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new class of oral anti-diabetic medications that improve glycaemia by reducing the amount of glucose being absorbed in the kidneys. SGLT2 inhibitors have been proven to improve blood pressure, cardiovascular health and kidney disease. Despite their beneficial clinical effects, their exact mechanism of action is not fully explored. The aim of this project was to investigate the effect of SGLT2 ...